{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:18:22Z","timestamp":1770409102670,"version":"3.49.0"},"reference-count":20,"publisher":"IMR Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Hosp Med"],"published-print":{"date-parts":[[2021,4,2]]},"abstract":"<jats:p>Given the critical physiological role of potassium, it is understandable that the development of severe hyperkalaemia requires effective management to reduce its effects, which include muscle weakness, paralysis and cardiac arrhythmias. Hyperkalaemia most often results from the failure of renal adaptation to potassium imbalance. Patients who are most susceptible to the development of hyperkalaemia include those with chronic kidney disease and those with heart failure. These patients are often treated with renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors, such as angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers, but the development of hyperkalaemia can require down-titration or cessation of RAAS inhibitors. This presents a significant challenge to nephrologists, cardiologists and healthcare professionals treating these patients as this can prevent them from receiving maximum guideline-directed RAAS inhibitor therapy. Panellists in this roundtable discussion shared their clinical experiences of using potassium binders to manage hyperkalaemia in patients with chronic kidney disease and patients with heart failure (illustrated with case studies) in Northern Ireland and considered recommendations for the implementation and maintenance of chronic potassium-lowering treatment.<\/jats:p>","DOI":"10.12968\/hmed.2021.0215","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T13:58:42Z","timestamp":1619531922000},"page":"1-11","source":"Crossref","is-referenced-by-count":4,"title":["Practical guidance for the use of potassium binders in the management of hyperkalaemia in patients with heart failure and\/or chronic kidney disease"],"prefix":"10.31083","volume":"82","author":[{"given":"Patricia","family":"Campbell","sequence":"first","affiliation":[{"name":"Craigavon Hospital, Southern HSC Trust, Portadown, Craigavon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"McKeveney","sequence":"additional","affiliation":[{"name":"Downe Hospital, South Eastern Trust, Downpatrick"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Donegan","sequence":"additional","affiliation":[{"name":"Daisy Hill Hospital, Newry"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Ataliotis","sequence":"additional","affiliation":[{"name":"Downe Hospital, SE HSC Trust, Downpatrick"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Patton","sequence":"additional","affiliation":[{"name":"Craigavon Hospital, Southern HSC Trust, Portadown, Craigavon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Mullan","sequence":"additional","affiliation":[{"name":"Antrim Hospital, Northern HSC Trust, Antrim"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.018"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000479802"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-0502-6"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.100461"},{"issue":"11","key":"B10","first-page":"S212","volume":"21","author":"Epstein M","year":"2015","journal-title":"Am J Manag Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.09.001"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02920320"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.168"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-018-0413-9"},{"issue":"4","key":"B17","volume":"1","author":"Mushiyakh Y","year":"2012","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035279"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06060612"},{"issue":"20","key":"B23","first-page":"30618","volume":"0025","author":"Palmer BF","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq502"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00258.x"},{"issue":"3","key":"B28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"Rosano GMC","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31818f222b"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/pdf\/10.12968\/hmed.2021.0215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:02:08Z","timestamp":1770372128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/82\/4\/10.12968\/hmed.2021.0215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,2]]}},"alternative-id":["10.12968\/hmed.2021.0215"],"URL":"https:\/\/doi.org\/10.12968\/hmed.2021.0215","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]}}}